News
Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback